Influenza

Primary Efficacy Objective:  To evaluate the efficacy of a single, oral dose of S-033188 compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza Secondary Efficacy Objectives:  To evaluate the efficacy of a single, oral dose of S-033188 compared with oseltamivir 75 mg twice daily (BID) for 5 days by measuring the time to improvement of influenza symptoms in patients with influenza  To evaluate the efficacy of a single, oral dose of S-033188 compared with placebo by measuring the secondary endpoints in patients with influenza  To evaluate the efficacy of a single, oral dose of S-033188 compared with oseltamivir 75 mg BID for 5 days by measuring the secondary endpoints in patients with influenza

S-033188

S-033188

Tablet

20 mg

Primary Endpoint:
The primary efficacy endpoint will be the time to improvement of influenza symptoms
(with modification for preexisting symptoms).
Secondary Endpoints:
● Proportion of patients positive for virus titer and proportion of patients positive by
reverse transcription polymerase chain reaction (RT-PCR) at each time point
● Change from baseline in virus titer and in the amount of virus (RT-PCR) at each
time point
● Area under the curve adjusted by baseline in virus titer and in the amount of virus
RNA (RT-PCR)
● Time to cessation of viral shedding by virus titer and by RT-PCR
● Proportion of patients whose symptoms has been improved at each time point
● Time to alleviation of symptoms (cough, sore throat, headache, nasal congestion,
feverishness or chills, muscle or joint pain, and fatigue)
● Time to improvement in the 4 systemic symptoms (headache, feverishness/chills,
muscle/joint pain, and fatigue)
● Time to improvement in the 3 respiratory symptoms (cough, nasal congestion,
and sore throat)
● Time to resolution of fever
● Proportion of patients reporting normal temperature at each time point
● Body temperature at each time point
● Time to improvement of each influenza symptom
● Time to return to preinfluenza health status
● Requirement for systemic antibiotics for infections secondary to influenza
infection
● Incidence of influenza-related complications (hospitalization, death, sinusitis,
bronchitis, otitis media, and radiologically confirmed pneumonia)
● Intrahousehold infection rate (for Japan only)
Other Endpoints:
● Serum influenza antibody titer
● Polymorphic and treatment-emergent amino acid substitutions in the PA gene
● Drug susceptibility in patients with evaluable virus
● Health Economic Outcomes
- EQ-5D-5L
- WP questionnaire

1. Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements (see Section 7.1).
2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
3. Patients with a duration of influenza symptoms confirmed by all of the following:
a. Fever ≥ 38ºC (axillary) during the predose examinations or > 4 hours after dosing of antipyretics if they were taken
b. At least 1 each of the following general and respiratory symptoms associated with influenza (excluding those that are chronic and existed in the 30 days prior to the influenza episode) is present with a severity of moderate or greater:
i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue)
ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
4. The time interval between the onset of symptoms and the predose examinations (Screening) is 48 hours or less. The onset of symptoms is defined as either:
a. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
b. Time when the patient experiences at least 1 new general or respiratory symptom
5. If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of S-033188 or oseltamivir (see Section 6.3.1 for approved contraceptive requirements).
6. Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:
a. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
b. Endocrine disorders (including diabetes mellitus)
c. Residents of long-term care facilities (eg, nursing homes)
d. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus (HIV) infection with a CD4 count > 350 cells/mm3 within the last 6 months)
e. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
f. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
g. Adults aged ≥ 65 years
h. American Indians and Alaskan Natives
i. Blood disorders (such as sickle cell disease)
j. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
k. Morbid obesity (body mass index ≥ 40)

1. Patients with severe influenza virus infection requiring inpatient treatment.
2. Patients with known allergy to oseltamivir (Tamiflu®).
3. Patients unable to swallow tablets or capsules.
4. Patients who have previously received S-033188.
5. Patients weighing < 40 kg.
6. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:
a. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
b. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
9. Patients with liver disease associated with hepatic impairment.
10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
12. Patients with immunosuppression following organ or bone marrow transplants.
13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
16. Patients with current creatinine clearance ≤ 60 mL/min (≤ 30 mL/min in Japan).
17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions.